Ventripoint Diagnostics Ltd. (TSXV:VPT)
Canada · Delayed Price · Currency is CAD | Market Cap | 14.47M -13.8% |
| Revenue (ttm) | 147.77K +8.8% |
| Net Income | -2.32M |
| EPS | -0.01 |
| Shares Out | 192.88M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 82,312 |
| Open | 0.0700 |
| Previous Close | 0.0650 |
| Day's Range | 0.0700 - 0.0750 |
| 52-Week Range | 0.0650 - 0.1900 |
| Beta | 0.09 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 27, 2026 |
About Ventripoint Diagnostics
Ventripoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools that monitor patients with heart disease worldwide. The company offers Ventripoint Medical System (VMS), which transforms standard 2D and 3D echocardiography and a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient’s heart chambers. It also provides VMS+ software, 2D and 3D ultrasound models. In addition, it develops a suite of application... [Read more]
Financial Performance
In 2025, Ventripoint Diagnostics's revenue was 179,928, an increase of 89.06% compared to the previous year's 95,172. Losses were -3.20 million, -34.95% less than in 2024.
Financial StatementsNews
Ventripoint Announces Extension of Non-Brokered Unit Private Placement
Toronto, Ontario – TheNewswire - October 30, 2026 – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”, TSXV:VPT) announces that it will seek approval of TSX Venture Exchange (“ TSXV...
Ventripoint Diagnostics Transcript: Investor update
The commercialization foundation is in place, with subscriptions, demonstrations and a qualified pipeline supporting a stated push toward scale. Innovate BC-backed Providence placements, international programs and growth financing are central to execution.
Ventripoint Provides Corporate Update and Announces Shareholder Videoconference Call
Toronto, Canada – TheNewswire - October 6, 2026 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company ") ( TSXV:VPT; OTC:VPTDF), a leading provider of innovative AI-powered cardiac diagnos...
Ventripoint Announces Successful Completion of Annual Quality and Regulatory Audits
Toronto, Ontario (September 24, 2026) – TheNewswire - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT; OTC:VPTDF) today announced the completion of its annual quality and ...
Ventripoint Issues Shares for Payment of Debenture Interest
Toronto, Ontario – TheNewswire - September 14, 2026 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “ Corporation ”, TSXV:VPT) announces it has received approval from the TSX Venture Exchange (“ ...
Ventripoint Closes First Tranche of Private Placement Financing and Engages Strategic Advisors to Accelerate Commercialization of VMS+™ Technology
Toronto, Ontario – TheNewswire - September 8, 2026 – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”, TSXV: VPT; OTC: VPTDF) today announced several strategic initiatives to stren...
Ventripoint Diagnostics MD&A: Q2 2026
Ventripoint Diagnostics filed a regulatory document on August 31, 2026 disclosing important business information.
Ventripoint Diagnostics Report: Q2 2026
Ventripoint Diagnostics published a report on August 31, 2026 containing material business information for investors and shareholders.
UniDoc Health Signs MOU with Ventripoint Diagnostics to Evaluate Remote Cardiac Assessment and Screening Platform
Proposed collaboration would combine UniDoc's connected-care infrastructure with Ventripoint's AI-enabled cardiac imaging platform VANCOUVER, BC / ACCESS Newswire / August 20, 2026 / UniDoc Health Cor...
Ventripoint Expands Subscription Access for FDA-Cleared AI Cardiac Imaging
TORONTO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV: VPT; OTC: VPTDF), a leader in AI-assisted cardiac imaging, today announced the next phas...
Ventripoint Diagnostics Announces Cancellation and Re-Grant of Options, Grant of Annual Incentive Options and Private Placement
Toronto, Ontario – The Newswire – August 7, 2026 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company ") (TSXV:VPT; OTC:VPTDF) announces that it incorrectly granted 7,246,250 stock options...
UniDoc Health and Ventripoint Diagnostics Sign MOU to Evaluate Scalable Remote Cardiac Assessment and Screening Platform
Proposed collaboration would combine UniDoc Health Cubes and connected-care infrastructure with Ventripoint's AI-enabled VMS+™ platform in a hub-and-spoke care model Toronto, Ontario – TheNewswire –...
Ventripoint Strengthens Board with Appointment of MedTech Executive and Commercialization Leader Dr. Philip Toleikis
Toronto, Ontario – July 29, 2026 – TheNewswire - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company") (TSXV: VPT; OTC: VPTDF), a leader in AI-powered cardiac imaging, today announced the appo...
Ventripoint Issue Shares for Payment of Debenture Interest
Toronto, Ontario – TheNewswire - July 22, 2026 – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”, TSXV:VPT) announces it will satisfy debenture interest payment obligations with t...
Ventripoint Engages More Capital Ltd.
Pioneering Medical AI Company Moves to Increase Awareness of VMS+ System and Proprietary Knowledge Based Reconstruction Technology Toronto, Ontario – TheNewswire – July 22, 2026 - Ventripoint Diagno...
Ventripoint Diagnostics' VMS+ Technology Selected for World-First AI Cardiac Monitoring Study in Breast Cancer Patients
Ventripoint's VMS+ platform to be evaluated alongside a second AI technology in a landmark NHS study exploring earlier detection of chemotherapy-related heart damage Toronto, Ontario – TheNewswire –...
Ventripoint and Ollie Hinkle Heart Foundation Partner to Expand Access to AI-Powered Heart Imaging for Children Living with Heart Disease
Collaboration inspired by families' lived experiences aims to reduce barriers to advanced cardiac imaging and ensure no parent faces impossible decisions when seeking answers about their child's heart...
Ventripoint Diagnostics Announces Support for the Global Congenital Heart Disease Alliance
Toronto, Ontario – TheNewswire – June 15, 2026 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) a pioneer in advanced cardiac imaging, today announced its support...
Ventripoint Provides Videoconference Link to Annual General Meeting and Corporate Update
Toronto, Canada – TheNewswire - May 25, 2026 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company ") ( TSXV:VPT; OTC:VPTDF), a leading provider of innovative AI-powered cardiac diagnostic...
Ventripoint Announces Closing of $308,030 Non-Brokered Units Private Placement
Toronto, Ontario, May 22, 2026 – TheNewswire - Ventripoint Diagnostics Ltd. (“ Ventripoint” or the “Corporation ”) (TSXV:VPT) is pleased to announce the closing of a non-brokered private placement of ...
Ventripoint to Exhibit at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology
Toronto, Ontario – TheNewswire – May 4, 2026 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV:VPT; OTC:VPTDF) will exhibit at the 59th Annual Meeting of the Association for Europe...
Ventripoint Diagnostics Report: Q4 2025
Ventripoint Diagnostics published a report on May 1, 2026 containing material business information for investors and shareholders.
Ventripoint Diagnostics MD&A: Q4 2025
Ventripoint Diagnostics filed a regulatory document on May 1, 2026 disclosing important business information.
Ventripoint's VMS+ (TM) 4.0 Submitted for Regulatory Approval in China by Lishman Global Inc.
Toronto, Canada – TheNewswire - April 28, 2026 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSX-V:VPT, OTC:VPTDF), is proud to announce that its strategic partner, Lishman Global I...
Ventripoint's VMS+(TM) 4.0 Recognized with Gold Edison Award, Validating Leadership and Future Potential
Toronto, Canada – TheNewswire - April 20, 2026 – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Company ”) (TSX-V:VPT, OTC:VPTDF) , is proud to announce that its proprietary VMS+™ 4.0 ( Ventr...